Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

C. Lepage; M. Phelip; L. Cany; E. Maillard; A. Lievre; T. Chatellier; R. Faroux; J-C. Duchmann; M. Ben Abdelghani; G. Breysacher; P. Geoffroy; D. Pere-Verge; A. Pelaquier; D. Pillon; J. Ezenfis; Y. Rinaldi; A. Darut-Jouve; M. Duluc; A. Adenis; O. Bouché

doi:10.1093/annonc/mdw370.31

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

C. Lepage ^{1, 2} M. Phelip ³ L. Cany ⁴ E. Maillard ⁵ A. Lievre ⁶ T. Chatellier R. Faroux ⁷ J-C. Duchmann ⁸ M. Ben Abdelghani ⁹ G. Breysacher ¹⁰ P. Geoffroy ¹¹ D. Pere-Verge ¹² A. Pelaquier ¹³ D. Pillon ¹⁴ J. Ezenfis Y. Rinaldi A. Darut-Jouve ¹⁵ M. Duluc ¹⁶ A. Adenis ¹⁷ O. Bouché ¹⁸

1 LNC - Lipides - Nutrition - Cancer (U866)

2 Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon)

3 CHU Saint-Etienne

4 Polyclinique Francheville

5 Fédération Francophone de la Cancérologie Digestive, FFCD

6 Pontchaillou. Service des maladies de l'appareil digestif

7 Centre Hospitalier Départemental Les Oudairies

8 Service gastro-entérologie et hépatologie

9 Service d'oncologie médicale [CHU Strasbourg]

10 Hôpitaux Civils Colmar

11 Institut de Chimie de Strasbourg

12 Centre hospitalier Saint Joseph - Saint Luc [Lyon]

13 CH Montélimar

14 Centre Hospitalier Fleyriat [Bourg en Bresse]

15 Clinique Drévon

16 Service d'oncologie digestive et hépato-gastro-entérologie [Hôpital de la Timone - APHM]

17 Center Oscar Lambret

18 CHU Reims - Centre Hospitalier Universitaire de Reims

Abstract : Background: PRODIGE 13 is a cooperative prospective multicentre controlled phase III trial evaluating by double randomisation the impact of intensive radiological monitoring versus a standard one and CEA monitoring versus no monitoring in Stage II or III colorectal cancer. This abstract describes patient's baseline characteristics. Methods: Recommendations for colorectal cancer, according to various scientific societies have been based on heterogeneous clinical trials, and indeed mainly on expert opinions. Differences still exist particularly concerning the imaging techniques used. The CEA dosage is also poorly evaluated. Despite their limits, recent trials suggest that survival is increased thanks to clinical monitoring combined with hepatic and pulmonary imaging and possibly CEA assay. PRODIGE 13 is a large randomised trial of monitoring strategy and will evaluate the strategies to...

Keywords : Gastrointestinal tumours Colorectal

Type de document :

Communication dans un congrès

41st Congress of the European-Society-for-Medical-Oncology (ESMO), Oct 2016, Copenhague, Denmark. Annals of oncology 27 (suppl_6), pp.483P, 2016, Abstract Book of the 41st ESMO Congress (ESMO 2016). 〈https://academic.oup.com/annonc/article-abstract/27/suppl_6/483P/2799278/Effect-of-5-years-of-imaging-and-CEA-follow-up-to?redirectedFrom=fulltext〉. 〈10.1093/annonc/mdw370.31〉

Domaine :

Sciences du Vivant [q-bio] / Cancer

Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01507441
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : jeudi 13 avril 2017 - 10:50:30
Dernière modification le : lundi 27 août 2018 - 09:44:39

C. Lepage, M. Phelip, L. Cany, E. Maillard, A. Lievre, et al.. Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. 41st Congress of the European-Society-for-Medical-Oncology (ESMO), Oct 2016, Copenhague, Denmark. Annals of oncology 27 (suppl_6), pp.483P, 2016, Abstract Book of the 41st ESMO Congress (ESMO 2016). 〈https://academic.oup.com/annonc/article-abstract/27/suppl_6/483P/2799278/Effect-of-5-years-of-imaging-and-CEA-follow-up-to?redirectedFrom=fulltext〉. 〈10.1093/annonc/mdw370.31〉. 〈hal-01507441〉

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Métriques

89

Contact

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

Lien texte intégral

Identifiants

Collections

Citation

Exporter

Partager

Métriques

89

Contact